Open Access Clinical Study
Gynecomastia treatment with tamoxifen or tamoxifen followed by letrozole: prototype clinical study
Stefanos Zervoudis1,2,*
, Georgios Iatrakis1,2, Panagiotis Tsikouras3, Panagiotis Peitsidis1,2, Angeliki Sarella2, Christos Ampatzis4
1Rea Maternity Hospital: Breast Unit, Athens, Greece
2 University of West Attica, Athens, Greece
3 University Hospital of Alexandroupolis, Greece
4 “St Andrew” General Hospital of Patras, Patra, Greece
*Corresponding author:
Stefanos Zervoudis, Rea Hospital, 283 Syggrou Avenue, Tel.: +302109495000
Email: szervoud@otenet.gr
Download PDF
Published: 21 May 2024; DOI: 10.61873/XVQY6568
Abstract
Gynecomastia is very common cause of a patient’s visit to a mastology office. Gynecomastia is experienced in up to 70% of mid-puberty males and in up to 65% of middle-aged men. The treatment starts with the identification of the cause, but in most cases the patient is treated with tamoxifen, aromatase inhibitors, liposuction or surgery. Τreatment of gynecomastia is not well standarized. In our prospective study, we examined the use of tamoxifen followed by letrozole and a clinically important reduction was achieved, when compared with those who were treated only with tamoxifen. Further research needs to be conducted in order to confirm this promising protocol.
Keywords:
gynecomastia, tamoxifen, aromatase inhibitors, letrozole
Please cite as:
Zervoudis S., Iatrakis G., Tsikouras G., Peitsidis P., Sarella A., Ampatzis C. Gynecomastia treatment with Tamoxifen or Tamoxifen followed by Letrozole: Prototype Clinical Study. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38 (2): 99-106 (2024). DOI: 10.61873/XVQY6568